title: Hodgkin's lymphoma: current treatment strategies and novel approaches.
abstract: Approximately 80% of Hodgkin's lymphoma (HL) patients achieve long-term remission after primary chemotherapy or chemo/radiotherapy. Despite these excellent results, further treatment improvement is necessary. HL therapy is associated with severe acute and long-term toxicities. Thus, a major aim of clinical HL research is to evaluate novel schemes that are less toxic than current standard regimens without being less effective. Another focus is the treatment of patients with multiple relapses. Standard treatment for these patients has not yet been defined, and their prognosis is still poor. Reduced-intensity conditioning allogeneic stem cell transplantation was recently shown to be effective in carefully selected young chemosensitive patients. Furthermore, new strategies such as antibody- and small-molecule-based therapy have demonstrated encouraging results in preclinical studies and the first clinical trials.
authors.affiliation: First Department of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany. dennis.eichenauer@uk-koeln.de
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Eichenauer
authors.forename: Michael
authors.initials: M
authors.lastname: Fuchs
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D000077269:Lenalidomide; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide